Dyslipidemia
ICD-10 E78 · Disorders of lipoprotein metabolism and other lipidemias
Plan de suivi
National Institute for Health and Care Excellence (NICE) (2024) · NICE NG238 Cholestérol on or starting lipid-lowering treatment · baseline before statins, 2 to 3 months after starting or changing treatment, then annually “Measure liver transaminase and full lipid profile at 2 to 3 months after starting or changing lipid-lowering treatment. Offer an annual full lipid profile to inform discussions about secondary prevention of CVD.” — NG238 1.11.1, 1.11.9
Cholestérol HDL CVD risk assessment · baseline, then annually “Measure both total blood cholesterol and high-density lipoprotein (HDL) cholesterol to achieve the best estimate of CVD risk.” — NG238 1.4.1
Alanine aminotransférase on statins · 2 to 3 months after starting, then at 12 months, then only if clinically indicated “Measure liver transaminase and full lipid profile at 2 to 3 months after starting or changing lipid-lowering treatment. Measure liver transaminase at 12 months, but not again unless clinically indicated.” — NG238 1.11.1, 1.11.2
Triglycérides elevated result · repeat within 2 weeks if elevated and specialist assessment may be needed “Repeat testing within 2 weeks for elevated levels requiring specialist assessment.” — NG238 1.4.7
Plan de suivi
European Society of Cardiology / European Atherosclerosis Society (2011) · ESC/EAS Guidelines for the management of dyslipidaemias Cholestérol HDL risk marker
Sources
Monitoring frequencies from NICE NG238.